JARDIANCE®: consider our THREE CLINICAL USES1
Type 2 diabetes mellitus (T2DM)
In adults with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease
Heart failure (HF)
Quick links
JARDIANCE® – the #1 dispensed SGLT2i in Canada3*
JARDIANCE®: dosing across our THREE INDICATIONS1
In adults with T2DM  | In adults with T2DM and ESTABLISHED CV DISEASE  | In adults with HF  | |
|---|---|---|---|
| AS MONOTHERAPY TO IMPROVE GLYCEMIC CONTROL | AS ADD-ON COMBINATION THERAPY TO IMPROVE GLYCEMIC CONTROL | AS ADD-ON COMBINATION THERAPY TO REDUCE THE INCIDENCE OF CV DEATH | AS ADD-ON COMBINATION THERAPY FOR THE TREATMENT OF HF |
| JARDIANCE® (empagliflozin) is indicated as monotherapy for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance. | JARDIANCE® is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control. | JARDIANCE® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in adult patients with T2DM and established cardiovascular disease. | JARDIANCE® is indicated in adults as an adjunct to standard of care therapy for the treatment of heart failure. Limitation of use: JARDIANCE® is not recommended for the emergency treatment of acute heart failure. |
| Convenient, once-daily oral dosing | |||
JARDIANCE® 10 mg  | JARDIANCE® 25 mg  | JARDIANCE® 10 mg | JARDIANCE® 10 mg |
Once daily | |||
JARDIANCE® can be used in adults with T2DM who have an eGFR ≥30 mL/min/1.73 m2 | JARDIANCE® can be used without dosage adjustment in adults with HF who have an eGFR ≥20 mL/min/1.73 m2 Not recommended for use in HF patients with an eGFR <20 mL/min/1.73 m2. | ||
Adapted from JARDIANCE® Product Monograph.
In adults with T2DM | |
|---|---|
| AS MONOTHERAPY TO IMPROVE GLYCEMIC CONTROL | AS ADD-ON COMBINATION THERAPY TO IMPROVE GLYCEMIC CONTROL |
| JARDIANCE® (empagliflozin) is indicated as monotherapy for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance. | JARDIANCE® is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control. |
In adults with T2DM and ESTABLISHED CV DISEASE | In adults with HF |
| AS ADD-ON COMBINATION THERAPY TO REDUCE THE INCIDENCE OF CV DEATH | AS ADD-ON COMBINATION THERAPY FOR THE TREATMENT OF HF |
| JARDIANCE® is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in adult patients with T2DM and established cardiovascular disease. | JARDIANCE® is indicated in adults as an adjunct to standard of care therapy for the treatment of chronic heart failure. |
| Convenient, once-daily oral dosing | |
|---|---|
In adults with T2DM | |
| AS MONOTHERAPY TO IMPROVE GLYCEMIC CONTROL | AS ADD-ON COMBINATION THERAPY TO IMPROVE GLYCEMIC CONTROL |
JARDIANCE® 10 mg | |
JARDIANCE® 25 mg | |
In adults with T2DM and ESTABLISHED CV DISEASE | In adults with HF |
| AS ADD-ON COMBINATION THERAPY TO REDUCE THE INCIDENCE OF CV DEATH | AS ADD-ON COMBINATION THERAPY FOR THE TREATMENT OF HF |
JARDIANCE® 10 mg | JARDIANCE® 10 mg |
Once daily | |
| Renal impairment | |
|---|---|
In adults with T2DM | |
| |
| AS MONOTHERAPY TO IMPROVE GLYCEMIC CONTROL | AS ADD-ON COMBINATION THERAPY TO IMPROVE GLYCEMIC CONTROL |
In adults with T2DM and ESTABLISHED CV DISEASE | In adults with HF |
| AS ADD-ON COMBINATION THERAPY TO REDUCE THE INCIDENCE OF CV DEATH | AS ADD-ON COMBINATION THERAPY FOR THE TREATMENT OF HF |
|
|
Adapted from JARDIANCE® Product Monograph.
JARDIANCE® renal dosing considerations
Dosage recommendations based on eGFR1
Dosing considerations
- Assess renal function prior to initiation and regularly thereafter
- Assess volume status and, if necessary, correct volume depletion prior to initiation
- When added to insulin or an insulin secretagogue (e.g., sulfonylurea), a lower dose of the insulin or insulin secretagogue may be considered to reduce the risk of hypoglycemia
- Use with caution in patients taking diuretics, particularly loop diuretics
- Patients hospitalized for acute HF (de novo or decompensated chronic HF) should be adequately stabilized and should receive
HF therapies in accordance with clinical guidelines
Considerations for special populations
Renal impairment: the glucose-lowering efficacy of JARDIANCE® declines with decreasing renal function.
Hepatic impairment: No dosage adjustment needed for patients with mild/moderate hepatic impairment. Not recommended for use in patients with severe hepatic impairment.
Geriatrics (≥65 years of age): No dosage adjustment required based on age. However, renal function and risk of volume depletion should be taken into account.
Please see the Product Monograph for complete dosing and administration information.
HCP=healthcare professional; T2DM=type 2 diabetes mellitus; eCVD=established cardiovascular disease; HF=heart failure; SGLT2i=sodium-glucose co-transporter 2 inhibitor; eGFR=estimated glomerular filtration rate; ESRD=end-stage renal disease.
* Comparative clinical significance not established.
